{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T16:06:10Z","timestamp":1790784370987,"version":"4.1.0"},"reference-count":65,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["tmreviews.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transfusion Medicine Reviews"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1016\/j.tmrv.2017.04.001","type":"journal-article","created":{"date-parts":[[2017,4,25]],"date-time":"2017-04-25T02:46:27Z","timestamp":1493088387000},"page":"258-263","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Adjuncts to Blood Component Therapies for the Treatment of Bleeding in the Intensive Care Unit"],"prefix":"10.1016","volume":"31","author":[{"given":"Jerrold H.","family":"Levy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamrouz","family":"Ghadimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quintin J.","family":"Quinones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel R.","family":"Bartz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Welsby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl. 3","key":"10.1016\/j.tmrv.2017.04.001_bb0005","doi-asserted-by":"crossref","first-page":"iii18","DOI":"10.1093\/bja\/aew358","article-title":"Perioperative management of the bleeding patient","volume":"117","author":"Ghadimi","year":"2016","journal-title":"Br J Anaesth"},{"issue":"6","key":"10.1016\/j.tmrv.2017.04.001_bb0010","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1213\/ANE.0b013e3182354b7e","article-title":"Activation of the hemostatic system during cardiopulmonary bypass","volume":"113","author":"Sniecinski","year":"2011","journal-title":"Anesth Analg"},{"issue":"5","key":"10.1016\/j.tmrv.2017.04.001_bb0015","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1111\/trf.12431","article-title":"Fibrinogen as a therapeutic target for bleeding: a review of critical levels and replacement therapy","volume":"54","author":"Levy","year":"2014","journal-title":"Transfusion"},{"issue":"4","key":"10.1016\/j.tmrv.2017.04.001_bb0020","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1097\/ALN.0000000000000608","article-title":"Prothrombin complex concentrates in trauma and perioperative bleeding","volume":"122","author":"Grottke","year":"2015","journal-title":"Anesthesiology"},{"issue":"5","key":"10.1016\/j.tmrv.2017.04.001_bb0025","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1213\/ANE.0000000000001188","article-title":"Prothrombin complex concentrates for bleeding in the perioperative setting","volume":"122","author":"Ghadimi","year":"2016","journal-title":"Anesth Analg"},{"issue":"5","key":"10.1016\/j.tmrv.2017.04.001_bb0030","doi-asserted-by":"crossref","first-page":"S1814","DOI":"10.1016\/S0003-4975(01)03218-0","article-title":"Pharmacologic preservation of the hemostatic system during cardiac surgery","volume":"72","author":"Levy","year":"2001","journal-title":"Ann Thorac Surg"},{"issue":"1","key":"10.1016\/j.tmrv.2017.04.001_bb0035","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.anclin.2012.10.006","article-title":"Point of care devices for assessing bleeding and coagulation in the trauma patient","volume":"31","author":"Theusinger","year":"2013","journal-title":"Anesthesiol Clin"},{"issue":"5","key":"10.1016\/j.tmrv.2017.04.001_bb0040","first-page":"368","article-title":"Evaluation and management of bleeding during cardiac surgery","volume":"4","author":"Levy","year":"2005","journal-title":"Curr Hematol Rep"},{"issue":"9734","key":"10.1016\/j.tmrv.2017.04.001_bb0045","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0140-6736(10)60939-7","article-title":"Antifibrinolytic therapy: new data and new concepts","volume":"376","author":"Levy","year":"2010","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.tmrv.2017.04.001_bb0050","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.blre.2014.09.003","article-title":"Fibrinolysis and the control of blood coagulation","volume":"29","author":"Chapin","year":"2015","journal-title":"Blood Rev"},{"issue":"1","key":"10.1016\/j.tmrv.2017.04.001_bb0055","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1177\/106002809703100109","article-title":"Rhabdomyolysis induced by epsilon-aminocaproic acid","volume":"31","author":"Seymour","year":"1997","journal-title":"Ann Pharmacother"},{"issue":"3","key":"10.1016\/j.tmrv.2017.04.001_bb0060","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1097\/ALN.0b013e318264c644","article-title":"Point-of-care testing: a prospective, randomized clinical trial of efficacy in coagulopathic cardiac surgery patients","volume":"117","author":"Weber","year":"2012","journal-title":"Anesthesiology"},{"issue":"2","key":"10.1016\/j.tmrv.2017.04.001_bb0065","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1055\/s-0036-1592302","article-title":"Plasmin (ogen) at the nexus of fibrinolysis, inflammation, and complement","volume":"43","author":"Foley","year":"2017","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.tmrv.2017.04.001_bb0070","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.ebiom.2016.02.011","article-title":"Complement activation in arterial and venous thrombosis is mediated by plasmin","volume":"5","author":"Foley","year":"2016","journal-title":"EBioMedicine"},{"issue":"9734","key":"10.1016\/j.tmrv.2017.04.001_bb0075","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0140-6736(10)60835-5","article-title":"Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial","volume":"376","author":"Shakur","year":"2010","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.tmrv.2017.04.001_bb0080","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1056\/NEJMoa1606424","article-title":"Tranexamic acid in patients undergoing coronary-artery surgery","volume":"376","author":"Myles","year":"2017","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.tmrv.2017.04.001_bb0085","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1053\/j.jvca.2010.02.018","article-title":"Changing from aprotinin to tranexamic acid results in increased use of blood products and recombinant factor VIIa for aortic surgery requiring hypothermic arrest","volume":"24","author":"Sniecinski","year":"2010","journal-title":"J Cardiothorac Vasc Anesth"},{"issue":"6","key":"10.1016\/j.tmrv.2017.04.001_bb0090","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1213\/ane.0b013e318184bc20","article-title":"The risks of aprotinin and tranexamic acid in cardiac surgery: a one-year follow-up of 1188 consecutive patients","volume":"107","author":"Martin","year":"2008","journal-title":"Anesth Analg"},{"issue":"1","key":"10.1016\/j.tmrv.2017.04.001_bb0095","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1124\/jpet.301.1.168","article-title":"Tranexamic acid, a widely used antifibrinolytic agent, causes convulsions by a gamma-aminobutyric acid(a) receptor antagonistic effect","volume":"301","author":"Furtmuller","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"issue":"2","key":"10.1016\/j.tmrv.2017.04.001_bb0100","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1097\/00000542-200208000-00016","article-title":"Pharmacokinetics of tranexamic acid during cardiopulmonary bypass","volume":"97","author":"Dowd","year":"2002","journal-title":"Anesthesiology"},{"issue":"5","key":"10.1016\/j.tmrv.2017.04.001_bb0105","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1111\/j.1600-0412.2012.01361.x","article-title":"Efficacy of tranexamic acid in the treatment of idiopathic and non-functional heavy menstrual bleeding: a systematic review","volume":"91","author":"Naoulou","year":"2012","journal-title":"Acta Obstet Gynecol Scand"},{"issue":"9","key":"10.1016\/j.tmrv.2017.04.001_bb0110","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1182\/blood-2014-08-552000","article-title":"How I use fibrinogen replacement therapy in acquired bleeding","volume":"125","author":"Levy","year":"2015","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.tmrv.2017.04.001_bb0115","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1160\/TH04-12-0799","article-title":"Relationship between factor XIII activity, fibrinogen, haemostasis screening tests and postoperative bleeding in cardiopulmonary bypass surgery","volume":"93","author":"Blome","year":"2005","journal-title":"Thromb Haemost"},{"issue":"2","key":"10.1016\/j.tmrv.2017.04.001_bb0120","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1111\/j.1538-7836.2007.02297.x","article-title":"The decrease of fibrinogen is an early predictor of the severity of postpartum hemorrhage","volume":"5","author":"Charbit","year":"2007","journal-title":"J Thromb Haemost"},{"issue":"3","key":"10.1016\/j.tmrv.2017.04.001_bb0125","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1097\/00000542-199603000-00032","volume":"84","year":"1996","journal-title":"Anesthesiology"},{"key":"10.1016\/j.tmrv.2017.04.001_bb0130","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/j.jtcvs.2011.03.015","article-title":"Bleeding and management of coagulopathy","volume":"142","author":"Sniecinski","year":"2011","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.tmrv.2017.04.001_bb0135","article-title":"Fibrinogen as a therapeutic target for bleeding: a review of critical levels and replacement therapy","author":"Levy","year":"2013","journal-title":"Transfusion"},{"key":"10.1016\/j.tmrv.2017.04.001_bb0140","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s13049-015-0165-4","article-title":"Effect of coagulation factor concentrate administration on ROTEM(R) parameters in major trauma","volume":"23","author":"Ponschab","year":"2015","journal-title":"Scand J Trauma Resusc Emerg Med"},{"key":"10.1016\/j.tmrv.2017.04.001_bb0145","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/1757-7241-21-74","article-title":"Impact of fibrinogen concentrate alone or with prothrombin complex concentrate (+\/\u2212 fresh frozen plasma) on plasma fibrinogen level and fibrin-based clot strength (FIBTEM) in major trauma: a retrospective study","volume":"21","author":"Schlimp","year":"2013","journal-title":"Scand J Trauma Resusc Emerg Med"},{"issue":"1","key":"10.1016\/j.tmrv.2017.04.001_bb0150","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/s13054-016-1265-x","article-title":"The European guideline on management of major bleeding and coagulopathy following trauma: fourth edition","volume":"20","author":"Rossaint","year":"2016","journal-title":"Crit Care"},{"issue":"7","key":"10.1016\/j.tmrv.2017.04.001_bb0155","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1111\/j.1538-7836.2012.04752.x","article-title":"Fibrinogen levels during trauma hemorrhage, response to replacement therapy, and association with patient outcomes","volume":"10","author":"Rourke","year":"2012","journal-title":"J Thromb Haemost"},{"issue":"6","key":"10.1016\/j.tmrv.2017.04.001_bb0160","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1093\/bja\/aeu158","article-title":"Cryoprecipitate therapy","volume":"113","author":"Nascimento","year":"2014","journal-title":"Br J Anaesth"},{"issue":"2","key":"10.1016\/j.tmrv.2017.04.001_bb0165","doi-asserted-by":"crossref","first-page":"e24","DOI":"10.3324\/haematol.12151","article-title":"Reply. Pereira A. Cryoprecipitate versus commercial fibrinogen concentrate in patients who occasionally require a therapeutic supply of fibrinogen: risk comparison in the case of an emerging transfusion-transmitted infection. Haematologica 2007; 92:846\u20139","volume":"93","author":"Groner","year":"2008","journal-title":"Haematologica"},{"issue":"6","key":"10.1016\/j.tmrv.2017.04.001_bb0170","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1093\/bja\/aep089","article-title":"Bleeding management with fibrinogen concentrate targeting a high-normal plasma fibrinogen level: a pilot study","volume":"102","author":"Rahe-Meyer","year":"2009","journal-title":"Br J Anaesth"},{"issue":"3","key":"10.1016\/j.tmrv.2017.04.001_bb0175","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/j.jtcvs.2008.11.065","article-title":"Thromboelastometry-guided administration of fibrinogen concentrate for the treatment of excessive intraoperative bleeding in thoracoabdominal aortic aneurysm surgery","volume":"138","author":"Rahe-Meyer","year":"2009","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"5","key":"10.1016\/j.tmrv.2017.04.001_bb0180","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1093\/bja\/aeq058","article-title":"Recovery of fibrinogen after administration of fibrinogen concentrate to patients with severe bleeding after cardiopulmonary bypass surgery","volume":"104","author":"Solomon","year":"2010","journal-title":"Br J Anaesth"},{"issue":"6","key":"10.1016\/j.tmrv.2017.04.001_bb0185","doi-asserted-by":"crossref","first-page":"453","DOI":"10.3109\/00365513.2010.500396","article-title":"High-dose fibrinogen concentrate for haemostatic therapy of a major trauma patient with recent clopidogrel and aspirin intake","volume":"70","author":"Schochl","year":"2010","journal-title":"Scand J Clin Lab Invest"},{"issue":"2","key":"10.1016\/j.tmrv.2017.04.001_bb0190","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.jamcollsurg.2012.10.017","article-title":"Impact of fibrinogen levels on outcomes after acute injury in patients requiring a massive transfusion","volume":"216","author":"Inaba","year":"2013","journal-title":"J Am Coll Surg"},{"issue":"1","key":"10.1016\/j.tmrv.2017.04.001_bb0195","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1097\/ALN.0b013e3182715d4d","article-title":"Effects of fibrinogen concentrate as first-line therapy during major aortic replacement surgery: a randomized, placebo-controlled trial","volume":"118","author":"Rahe-Meyer","year":"2013","journal-title":"Anesthesiology"},{"issue":"9","key":"10.1016\/j.tmrv.2017.04.001_bb0200","first-page":"e275","article-title":"Comparing the viscoelastomeric fibrin polymerization assays FIBTEM(R) (ROTEM) vs. functional fibrinogen(R) (TEG): or why is a higher threshold for fibrinogen substitution better than a lower one?","volume":"54","author":"Schochl","year":"2016","journal-title":"Clin Chem Lab Med"},{"issue":"2","key":"10.1016\/j.tmrv.2017.04.001_bb0205","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1213\/ANE.0000000000000058","article-title":"The effectiveness of different functional fibrinogen polymerization assays in eliminating platelet contribution to clot strength in thromboelastometry","volume":"118","author":"Schlimp","year":"2014","journal-title":"Anesth Analg"},{"issue":"6","key":"10.1016\/j.tmrv.2017.04.001_bb0210","doi-asserted-by":"crossref","first-page":"e002066","DOI":"10.1161\/JAHA.115.002066","article-title":"Randomized, double-blinded, placebo-controlled trial of fibrinogen concentrate supplementation after complex cardiac surgery","volume":"4","author":"Ranucci","year":"2015","journal-title":"J Am Heart Assoc"},{"issue":"1","key":"10.1016\/j.tmrv.2017.04.001_bb0215","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1093\/bja\/aew169","article-title":"Randomized evaluation of fibrinogen vs placebo in complex cardiovascular surgery (REPLACE): a double-blind phase III study of haemostatic therapy","volume":"117","author":"Rahe-Meyer","year":"2016","journal-title":"Br J Anaesth"},{"issue":"7","key":"10.1016\/j.tmrv.2017.04.001_bb0220","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1001\/jama.2016.21037","article-title":"Effect of fibrinogen concentrate on intraoperative blood loss among patients with intraoperative bleeding during high-risk cardiac surgery: a randomized clinical trial","volume":"317","author":"Bilecen","year":"2017","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.tmrv.2017.04.001_bb0225","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1093\/bja\/aeu444","article-title":"Pre-emptive treatment with fibrinogen concentrate for postpartum haemorrhage: randomized controlled trial","volume":"114","author":"Wikkelso","year":"2015","journal-title":"Br J Anaesth"},{"issue":"5","key":"10.1016\/j.tmrv.2017.04.001_bb0230","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1097\/ALN.0b013e3181895bd8","article-title":"Perioperative hemostatic management of patients treated with vitamin K antagonists","volume":"109","author":"Levy","year":"2008","journal-title":"Anesthesiology"},{"issue":"1","key":"10.1016\/j.tmrv.2017.04.001_bb0235","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1186\/s13054-016-1422-2","article-title":"Nonvitamin K antagonist oral anticoagulant activity: challenges in measurement and reversal","volume":"20","author":"Brown","year":"2016","journal-title":"Crit Care"},{"issue":"3","key":"10.1016\/j.tmrv.2017.04.001_bb0240","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s12028-009-9310-0","article-title":"Prothrombin complex concentrates for oral anticoagulant therapy-related intracranial hemorrhage: a review of the literature","volume":"12","author":"Bershad","year":"2010","journal-title":"Neurocrit Care"},{"issue":"14","key":"10.1016\/j.tmrv.2017.04.001_bb0245","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1016\/j.clinthera.2011.01.011","article-title":"Modeling the cost-effectiveness of prothrombin complex concentrate compared with fresh frozen plasma in emergency warfarin reversal in the United Kingdom","volume":"32","author":"Guest","year":"2010","journal-title":"Clin Ther"},{"issue":"1","key":"10.1016\/j.tmrv.2017.04.001_bb0250","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1182\/blood-2012-02-408930","article-title":"Management of bleeding in acquired hemophilia a: results from the European Acquired Haemophilia (EACH2) registry","volume":"120","author":"Baudo","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.tmrv.2017.04.001_bb0255","first-page":"CD005011","article-title":"Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophilia","volume":"2","author":"Lin","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"10.1016\/j.tmrv.2017.04.001_bb0260","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1213\/01.ane.0000209023.96418.e5","article-title":"Small-dose recombinant activated factor VII (NovoSeven) in cardiac surgery","volume":"102","author":"Romagnoli","year":"2006","journal-title":"Anesth Analg"},{"issue":"1","key":"10.1016\/j.tmrv.2017.04.001_bb0265","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1161\/CIRCULATIONAHA.108.834275","article-title":"Safety and efficacy of recombinant activated factor VII: a randomized placebo-controlled trial in the setting of bleeding after cardiac surgery","volume":"120","author":"Gill","year":"2009","journal-title":"Circulation"},{"issue":"9","key":"10.1016\/j.tmrv.2017.04.001_bb0270","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1111\/j.1537-2995.2004.04052.x","article-title":"Transfusion medicine service policies for recombinant factor VIIa administration","volume":"44","author":"Goodnough","year":"2004","journal-title":"Transfusion"},{"key":"10.1016\/j.tmrv.2017.04.001_bb0275","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1213\/ANE.0b013e318228c6a9","article-title":"Recombinant activated factor VII: the controversial conundrum regarding its off-label use","volume":"113","author":"Karkouti","year":"2011","journal-title":"Anesth Analg"},{"issue":"3","key":"10.1016\/j.tmrv.2017.04.001_bb0280","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1001\/jama.295.3.293","article-title":"Thromboembolic adverse events after use of recombinant human coagulation factor VIIa","volume":"295","author":"O'Connell","year":"2006","journal-title":"JAMA"},{"issue":"19","key":"10.1016\/j.tmrv.2017.04.001_bb0285","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1056\/NEJMoa1006221","article-title":"Safety of recombinant activated factor VII in randomized clinical trials","volume":"363","author":"Levi","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tmrv.2017.04.001_bb0290","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1182\/asheducation-2010.1.465","article-title":"Optimal use of blood products in severely injured trauma patients","author":"Holcomb","year":"2010","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"6","key":"10.1016\/j.tmrv.2017.04.001_bb0295","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1097\/TA.0b013e3181a59ad5","article-title":"Improvements in early mortality and coagulopathy are sustained better in patients with blunt trauma after institution of a massive transfusion protocol in a civilian level I trauma center","volume":"66","author":"Dente","year":"2009","journal-title":"J Trauma"},{"issue":"6","key":"10.1016\/j.tmrv.2017.04.001_bb0300","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1056\/NEJMoa1502000","article-title":"Idarucizumab for Dabigatran Reversal","volume":"373","author":"Pollack","year":"2015","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.tmrv.2017.04.001_bb0305","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1056\/NEJMoa1607887","article-title":"Andexanet alfa for acute major bleeding associated with factor Xa inhibitors","volume":"375","author":"Connolly","year":"2016","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.tmrv.2017.04.001_bb0310","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1161\/CIRCULATIONAHA.114.013445","article-title":"Edoxaban effects on bleeding following punch biopsy and reversal by a 4-factor prothrombin complex concentrate","volume":"131","author":"Zahir","year":"2015","journal-title":"Circulation"},{"issue":"Suppl. 1","key":"10.1016\/j.tmrv.2017.04.001_bb0315","doi-asserted-by":"crossref","first-page":"S187","DOI":"10.1111\/jth.12949","article-title":"Reversal of oral factor Xa inhibitors by prothrombin complex concentrates: a re-appraisal","volume":"13","author":"Dzik","year":"2015","journal-title":"J Thromb Haemost"},{"issue":"12","key":"10.1016\/j.tmrv.2017.04.001_bb0320","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1016\/j.jcin.2014.06.014","article-title":"Direct oral anticoagulants: new drugs and new concepts","volume":"7","author":"Levy","year":"2014","journal-title":"JACC Cardiovasc Interv"},{"issue":"6","key":"10.1016\/j.tmrv.2017.04.001_bb0325","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1160\/TH09-11-0758","article-title":"Dabigatran etexilate\u2014a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity","volume":"103","author":"van Ryn","year":"2010","journal-title":"Thromb Haemost"}],"container-title":["Transfusion Medicine Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0887796317300123?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0887796317300123?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,21]],"date-time":"2019-09-21T16:43:44Z","timestamp":1569084224000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0887796317300123"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":65,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["S0887796317300123"],"URL":"https:\/\/doi.org\/10.1016\/j.tmrv.2017.04.001","relation":{},"ISSN":["0887-7963"],"issn-type":[{"value":"0887-7963","type":"print"}],"subject":[],"published":{"date-parts":[[2017,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adjuncts to Blood Component Therapies for the Treatment of Bleeding in the Intensive Care Unit","name":"articletitle","label":"Article Title"},{"value":"Transfusion Medicine Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tmrv.2017.04.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}